Ventum Cap Mkts Estimates Cresco Labs Q1 Earnings

Cresco Labs Inc. (OTCMKTS:CRLBF) – Equities research analysts at Ventum Cap Mkts issued their Q1 2025 EPS estimates for Cresco Labs in a research report issued to clients and investors on Wednesday, March 12th. Ventum Cap Mkts analyst A. Semple forecasts that the company will post earnings of ($0.03) per share for the quarter. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share. Ventum Cap Mkts also issued estimates for Cresco Labs’ Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.02) EPS and Q4 2025 earnings at ($0.02) EPS.

Separately, Atb Cap Markets cut shares of Cresco Labs from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 9th. Four analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $2.50.

Cresco Labs Trading Down 6.0 %

Shares of Cresco Labs stock opened at $0.70 on Friday. The firm has a 50-day moving average of $0.89 and a 200-day moving average of $1.21. The stock has a market cap of $341.70 million, a PE ratio of -3.50 and a beta of 1.79. Cresco Labs has a 52-week low of $0.70 and a 52-week high of $2.60. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.